SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Stealth BioTherapeutics Corp (Nasdaq – MITO)
BALA CYNWYD – August 1, 2022 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Stealth BioTherapeutics Corp (“Stealth BioTherapeutics” or the “Company”) (Nasdaq – MITO) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the Company’s agreement to be acquired by a consortium of investors led by Morningside Venture (I) Investments Ltd. for itself and on behalf of its affiliates (“Morningside”) and J. Wood Capital Advisors LLC (“J. Wood Capital”) (the “Consortium”) in an all-cash transaction. Pursuant to the merger agreement, the Consortium will buy MITO for $0.03125 per share and $0.375 per ADS in an all-cash transaction.
The investigation concerns whether the Stealth BioTherapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether the Consortium is paying too little for the Company.
If you own shares of Stealth BioTherapeutics stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.